Antisense Therapy in Clinical Oncology: Preclinical and Clinical Experiences
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 33 (3) , 221-238
- https://doi.org/10.1385/mb:33:3:221
Abstract
Nucleic acid molecules have emerged as versatile tools with promising utility as therapeutics for human diseases. The specificity of hybridization of an antisense oligonucleotide (AS ODN) to the target mRNA makes the AS strategy attractive to selectively modulate the expression of genes involved in the pathogenesis of malignant or non-malignant diseases. One AS drug has been approved for local therapy of cytomegalovirus retinitis, and a number of AS ODN are currently tested in clinical trials including ODN that target bcl-2, survivin, and DNA methyltransferase. The clinical studies indicate that AS ODN are well tolerated and may have therapeutic activity. In this overview, we summarize therapeutic concepts, clinical studies, and new promising molecular targets to treat human cancer with AS ODN.Keywords
This publication has 69 references indexed in Scilit:
- Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.2003
- RAF antisense oligonucleotide as a tumor radiosensitizerOncogene, 2003
- Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 WeeksInvestigational New Drugs, 2003
- Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.2001
- Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activationOncogene, 2000
- A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.2000
- Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.2000
- High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 2000
- Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)Journal of Clinical Oncology, 1999
- A Single BIR Domain of XIAP Sufficient for Inhibiting CaspasesJournal of Biological Chemistry, 1998